Institutions / Baker Bros. Advisors LP

Baker Bros. Advisors LP

CIK 1263508 · Institutionalso an insider · as of Mar 31, 2026
Portfolio value
$17.42B
Positions
84
As of
Mar 31, 2026

Portfolio trend

Portfolio value

$17.42B+2.0%
$17.42B$17.25B$17.08BQ4 '25Q1 '26

Positions

84-2.3%
868584Q4 '25Q1 '26

Top holdings

Mar 31, 2026View all 84 →
CompanyClassValueShares% of portfolio
Incyte Corp—$2.89B30,744,41216.6%
BeOne Medicines Ltd.ONCADR$2.61B8,799,05315.0%
Insmed Inc—$1.21B7,421,1117.0%
Madrigal Pharmaceuticals, Inc.—$1.12B2,141,7016.4%
ACADIA Pharmaceuticals Inc—$954.88M42,896,6905.5%
Revolution Medicines, Inc.—$929.26M9,555,3575.3%
Celcuity Inc.CELCCommon Stock$903.51M7,915,7925.2%
Kodiak Sciences Inc.KODCommon Stock$759.32M19,919,1864.4%
Kymera Therapeutics, Inc.—$721.06M8,657,2424.1%
Summit Therapeutics Inc.SMMTCommon Stock$689.97M36,391,0634.0%
Praxis Precision Medicines, Inc.—$564.86M1,753,1983.2%
Rhythm Pharmaceuticals, Inc.—$487.42M5,604,4832.8%
Alkermes plc.—$354.03M10,012,2672.0%
GRAIL, Inc.—$208.20M4,028,6141.2%
Edgewise Therapeutics, Inc.—$207.14M6,575,9401.2%
Ionis Pharmaceuticals Inc—$153.76M2,047,7270.9%
Kiniksa Pharmaceuticals International, plc—$136.08M2,826,2460.8%
Immunovant, Inc.IMVTCommon Stock$135.57M5,457,8810.8%
Roivant Sciences Ltd.—$134.84M4,867,7230.8%
Ideaya Biosciences, Inc.—$131.50M3,946,5150.8%
Arrowhead Pharmaceuticals, Inc.—$124.95M1,992,7830.7%
Stoke Therapeutics, Inc.—$108.64M3,336,6970.6%
Immatics N.V.—$107.42M10,916,6930.6%
AbCellera Biologics Inc.—$105.66M30,275,9380.6%
Abivax S.A.—$97.52M875,7960.6%

Activity

Mar 31, 2026View full history →
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
DateActionCompanyValueShares ΔPosition afterImpact
Q1 2026
as of
AddPraxis Precision Medicines, Inc.$201.92M+627K
+55.63%
1,753,198
3.24% of portfolio
high
Q1 2026
as of
AddInsmed Inc$135.45M+828K
+12.56%
7,421,111
6.97% of portfolio
high
Q1 2026
as of
AddGRAIL, Inc.$100.43M+1.9M
+93.19%
4,028,614
1.20% of portfolio
high
Q1 2026
as of
New15102Kaa8$74.87M+30.8M
30,750,000
0.43% of portfolio
high
Q1 2026
as of
ExitUltragenyx Pharmaceutical Inc.$-63.77M-2.8M
-100.00%
—
high
Q1 2026
as of
TrimIMCR
Immunocore Holdings Plc-Adr
ADR
$-47.89M-1.6M
-68.38%
734,397
0.13% of portfolio
medium
Q1 2026
as of
NewMirum Pharmaceuticals, Inc.$41.20M+446K
445,975
0.24% of portfolio
medium
Q1 2026
as of
ExitTerns Pharmaceuticals, Inc.$-38.38M-950K
-100.00%
—
medium
Q1 2026
as of
AddCrinetics Pharmaceuticals, Inc.$25.52M+703K
+42.61%
2,351,465
0.49% of portfolio
medium
Q1 2026
as of
AddELVN
Enliven Therapeutics, Inc.
Common Stock
$24.84M+634K
+233.52%
905,191
0.20% of portfolio
medium

Insider transactions

Also files Forms 3 / 4 / 5
DateActionCompanyValueShares ΔPosition afterImpact
May 8, 2026ExerciseINCY
Incyte Corp
Common Stock
$1.27M+15K
+0.05%
28,203,718
13.91% of shares
low
May 8, 2026ExerciseINCY
Incyte Corp
Common Stock
$1.27M+15K
+0.53%
2,833,039
1.40% of shares
low
May 22, 2026SellONC
BeOne Medicines Ltd.
Ordinary Shares
$65.6K-3K
-1.90%
142,570
<0.01% of shares
low
May 22, 2026SellONC
BeOne Medicines Ltd.
Ordinary Shares
$65.6K-3K
-1.90%
142,566
<0.01% of shares
low
May 22, 2026SellONC
BeOne Medicines Ltd.
Ordinary Shares
$65.4K-3K
-1.85%
145,326
<0.01% of shares
low
May 22, 2026SellONC
BeOne Medicines Ltd.
Ordinary Shares
$65.4K-3K
-1.85%
145,322
<0.01% of shares
low
Jun 17, 2026GrantMDGL
Madrigal Pharmaceuticals, Inc.
Common Stock
$0+908
+0.05%
1,948,876
8.44% of shares
low
Jun 17, 2026GrantMDGL
Madrigal Pharmaceuticals, Inc.
Common Stock
$0+908
+0.45%
203,721
0.88% of shares
low
Jun 11, 2026GrantONC
BeOne Medicines Ltd.
Ordinary Shares
$0+19K
+13.31%
161,550
0.01% of shares
low
Jun 11, 2026GrantONC
BeOne Medicines Ltd.
Ordinary Shares
$0+19K
+13.31%
161,546
0.01% of shares
low